In this issue of Cancer Cell, Li et al. develop novel tunable ON/OFF switch chimeric antigen receptor (CAR) circuits using clinically approved drugs based on the viral NS3 protease system. These platforms not only show superior controllability but also have high performance and compatibility, thereby providing versatile tools for precisely modulating CAR-T cells.